Collecting this in one place because it comes up every few weeks and the answer is always assembled from scratch. It is about thyroid monitoring, and it is deliberately narrow — everything I am not confident about is marked as such.
What is actually established
Routine calcitonin screening is not recommended and does more harm than good in this population — the false-positive rate is high and the workup is invasive. The rodent medullary thyroid carcinoma signal that drives the labelling has not translated into a human signal, but a personal or family history of MTC or MEN2 is a genuine contraindication rather than a formality. Separately, TSH is worth having at baseline because hypothyroidism explains fatigue that people will otherwise blame on the drug.
The condition it depends on
The caveat that a nodule found incidentally still needs following up on its own merits.
The practical version
Baseline worth having: TSH, and free T4 if TSH is abnormal. Calcitonin only if there is an actual MTC or MEN2 history.
What I am not sure about
So the question, as narrowly as I can put it: why calcitonin screening is not recommended when the label carries a thyroid warning, because those two facts look contradictory from the outside. I would rather have one careful answer than five confident ones.
TinaHashiRN said:Routine calcitonin screening is not recommended and does more harm than good in this population — the false-positive rate is high and the workup is…
Agreed, and site choice does not change absorption for the weekly agents, so rotating costs nothing pharmacologically.
TinaHashiRN said:Routine calcitonin screening is not recommended and does more harm than good in this population — the false-positive rate is high and the workup is…
Thyroid cancer screening labs for thyroid monitoring — addressing the boxed warning concern with actual data:
Calcitonin level: 4.0 pg/mL (normal <10). Checked at baseline, month 6, and month 12. Rock stable, no upward trend.
Thyroid ultrasound: normal, no nodules at month 12.
The MTC risk from rodent studies has not been confirmed in human post-marketing data across millions of patient-years. The boxed warning is a regulatory precaution based on animal data. While monitoring is prudent, the clinical risk appears to be negligible.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsAnswering the narrow version, because the broad one does not have a single answer. Site reactions are usually technique or temperature rather than the material. Injecting straight from the fridge stings more than injecting at room temperature, alcohol that has not dried carries into the puncture and burns, and re-using the same square inch produces the lump people worry about. Rotate genuinely — different quadrant each week, not different spot in the same quadrant.
JennaRN said:Agreed, and site choice does not change absorption for the weekly agents, so rotating costs nothing pharmacologically.
Can confirm. Same sequence, different timescale.